Pfizer Inc. $PFE Shares Acquired by Blume Capital Management Inc.

Blume Capital Management Inc. lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 194,533 shares of the biopharmaceutical company’s stock after buying an additional 5,900 shares during the period. Blume Capital Management Inc.’s holdings in Pfizer were worth $4,715,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in PFE. St. Johns Investment Management Company LLC raised its stake in Pfizer by 7.8% in the 2nd quarter. St. Johns Investment Management Company LLC now owns 26,877 shares of the biopharmaceutical company’s stock worth $651,000 after acquiring an additional 1,934 shares during the last quarter. Wallace Advisory Group LLC grew its stake in Pfizer by 16.6% during the 2nd quarter. Wallace Advisory Group LLC now owns 18,915 shares of the biopharmaceutical company’s stock valued at $479,000 after purchasing an additional 2,692 shares during the last quarter. Fiduciary Family Office LLC increased its holdings in shares of Pfizer by 20.2% in the second quarter. Fiduciary Family Office LLC now owns 17,370 shares of the biopharmaceutical company’s stock valued at $421,000 after purchasing an additional 2,917 shares during the period. IMG Wealth Management Inc. raised its stake in shares of Pfizer by 46.9% in the second quarter. IMG Wealth Management Inc. now owns 4,188 shares of the biopharmaceutical company’s stock worth $102,000 after purchasing an additional 1,338 shares during the last quarter. Finally, Jackson Thornton Wealth Management LLC acquired a new stake in shares of Pfizer during the second quarter worth about $272,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

PFE has been the topic of several research reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Citigroup increased their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Bank of America boosted their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Morgan Stanley cut their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Finally, UBS Group reissued a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $28.13.

Pfizer Stock Up 0.6%

PFE stock opened at $24.84 on Wednesday. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.17. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm’s fifty day moving average is $24.89 and its 200 day moving average is $24.13. The firm has a market cap of $141.23 billion, a PE ratio of 13.21, a P/E/G ratio of 0.82 and a beta of 0.55.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the company posted $0.60 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer’s payout ratio is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.